

ImmunoScape Establishes Scientific Advisory Board of Distinguished Immunology Experts

World-class scientists and physicians from Fred Hutchinson Cancer Research Center, St. Jude Children's Research Hospital, Massachusetts General Hospital and Harvard Medical School, will provide unique research perspectives and strategic direction

SINGAPORE and SAN DIEGO – January 28, 2021 – [ImmunoScape](#), a biotech company with an immunomics-based technology platform that provides novel insights into the human immune system, today announced the formation of its Scientific Advisory Board (SAB). The SAB is composed of leading scientists in immunology and oncology who will help to guide ImmunoScape's scientific strategy.

ImmunoScape's Deep Immunomics platform enables the characterization of a patient's immunome at ultra-high resolution. This technology reveals the immune system in action by directly observing the modulation of phenotype, function, and specificity of individual immune cells, at scale and over time. These insights can be provided to leading biopharma and academic partners to aid drug development efforts within multiple therapeutic areas, including immuno-oncology, infectious disease, and autoimmune disease.

The founding members of the SAB bring substantial scientific insight and expertise to assist the company. The founding members of the SAB include:

- **Evan Newell, Ph.D.:** Dr. Newell will serve as Chairman of the SAB. He is a co-founder of ImmunoScape and Associate Professor in the Vaccine and Infectious Disease Division at Fred Hutchinson Cancer Research Center. He pioneered the use of mass cytometry and pMHC-tetramer staining for phenotypic profiling of antigen-specific T cells and has published over 100 peer-reviewed scientific papers in the field of immunology. Newell began his pMHC-tetramer work at Stanford and continued to advance this methodology as a Principal Investigator at the Singapore Immunology Network, A*STAR, before joining Fred Hutchinson Cancer Research Center in Seattle.
- **Philip Greenberg, M.D.:** Dr. Greenberg is an internationally recognized expert in cancer immunotherapy and currently serves as the Head of Immunology at the Fred Hutchinson Cancer Research Center. He is also a Professor in the Departments of Medicine/Oncology and of Immunology at the University of Washington, and an Investigator of the Parker Institute for Cancer Immunotherapy. He has authored more than 280 manuscripts and received a long list of awards including the Cancer Research Institute's William B. Coley Award for Distinguished Research in Tumor Immunology, Society for Immunotherapy of Cancer Richard Smalley Memorial Career Award and many more. Dr. Greenberg's early discoveries indicated how to target diverse diseases with antigen-specific T cells and helped drive this growing field. His team continues to develop and test new strategies to genetically reprogram the patient's T cells to more effectively target and eradicate cancers.
- **Patrick Reeves, Ph.D.:** Dr. Reeves is a Team Leader in the Vaccine and Immunotherapy Center at Massachusetts General Hospital and an instructor in medicine at Harvard Medical School. His principal research focuses on understanding immune responses in the areas of infectious disease and immuno-oncology. The Reeves team utilize diverse analytical approaches including multi-parametric assays, coupled with robust data analysis and visualization methodologies, to

interrogate immune function and inform the development of novel vaccine and immune modulation strategies.

- **Paul Thomas, Ph.D.:** Dr. Thomas is a Member in the Department of Immunology at St. Jude Children’s Research Hospital and an adjunct Professor in the Department of Microbiology and Immunology at the University of Tennessee Health Sciences Center. Dr. Thomas performed his Ph.D. training at Harvard University, working on the innate immune response to Schistosoma-associated carbohydrates and their role in promoting Th2 responses. In 2009, he started his own lab within St. Jude, from which he has published over 150 peer-reviewed papers on TCR biology, immunological mechanisms of disease severity in human viral infections, and cellular immunology.

“To form this scientific advisory board, we brought together key thought leaders within immunology, across academia and industry alike,” said Michael Fehlings, Ph.D., Director of Scientific Affairs at ImmunoScape. “All of their careers have centered around developing next generation immunotherapies by gaining a greater understanding of immune cell function and responses. Their work has paved the way for ImmunoScape’s technology to have a greater impact, and their guidance will be invaluable as we look to further our development and commercialization efforts.”

“The future of immunotherapy development depends upon an enhanced ability to observe and analyze the T cell immune response at high resolution,” said Phil Greenberg, MD. “ImmunoScape’s platform represents a leap forward in this capability, rapidly providing insights into reasons for success or failure, and therefore has profound implications for this entire field of medicine. I am delighted to work with the SAB and with the company’s senior scientists in further advancing this technology.”

To learn more about ImmunoScape’s scientific advisory board and its technology, please visit <https://immunoscape.com/>.

About ImmunoScape

ImmunoScape is an immunomics-focused company with a technology platform that allows for immune profiling and characterization of the human immune response at extremely high resolution. The company's Deep Immunomics platform combines mass cytometry, single cell sequencing, and proprietary computational bioinformatics, data analysis, and visualization tools to provide novel, reproducible immune profiling information. This technology has been utilized across multiple therapeutic areas, especially in oncology and infectious disease, both to better understand immunotherapy safety and efficacy and to identify drug targets. For more information, please visit <https://immunoscape.com/>.

Media Contact

Kalyn Schieffer
kos@anzupartners.com